In vitro selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemisinin

Malaria Journal

Table 2 In vitro susceptibility testing of parental and resistant lines to anti-malarial drugs

Parasite line	QHS IC50	CQ IC50	PIP IC50	LMF IC50	AM IC50	DHA IC50	AS IC50
W2	2.85 ± 0.55	127.66 ± 1.96	64.18 ± 10.18	10.49 ± 0.06	3.92 ± 0.66	0.45 ± 0.16	0.60 ± 0.15
W2 c5B	9.13 ± 0.127	60.63 ± 8.62	51 ± 4.23	10.5 ± 0.27	5.44 ± 0.20	0.94 ± 0.26	2.35 ± 0.65
D6	3.06 ± 0.19	12.67 ± 0.03	44.37 ± 11.69	54.9 ± 3.99	8.74 ± 0.35	1.64 ± 0.45	1.454 ± 0.35
D6 c5B	8.26 ± 0.55	11.67 ± 2.05	55.46 ± 3.4	84.58 ± 1.64	12.26 ± 0.66	4.19 ± 1.03	7.66 ± 0.36
3D7	15.5 ± 0.95	13.36 ± 1.09	55.04 ± 0.81	54.52 ± 5.88	9.68 ± 2.17	2.78 ± 0.14	4.66 ± 0.93

W2 c5B = W2 P. falciparum line exposed to artemisinin, D6 c5B = D6 P. falciparum line exposed to artemisinin
QHS artemisinin, DHA dihydroartemisinin, CQ chloroquine diphosphate, PIP piperaquine phosphate, AM artemether, AS artesunate, LMF lumefantrine, ED50 50 % inhibitory concentration (in ng/ml; mean ± SD)

ISSN: 1475-2875